Live Breaking News & Updates on Carlos Garcia Parada

Posted on
344
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, as well as guidance for anticipated 2021 milestones.
“2021 is poised to be another exciting year for Rocket,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket. “We anticipate clinical data from all five of our gene therapy programs, initiation of our first in-house AAV cGMP production from our new manufacturing facility, and continued strengthening of our organization, manufacturing capabilities and infrastructure. We look forward to continued validation of our gene therapy platforms with updated results from registrational studies in FA and LAD-I, longer term findings in Danon Disease and PKD, and clinical proof-of ....

United States , New Jersey , Los Angeles , City Of , United Kingdom , Gaurav Shah , Claudine Prowse , Carlos Garcia Parada , Kinnari Patel , University Of California , California Institute For Regenerative Medicine , American Society Of Hematology Annual Meeting , Strategy Corporate Development , Fanconi Anemia Research Fund , Rocket Pharmaceuticals Inc , University Of Colorado , University Of Minnesota , Rocket Pharmaceuticals , Chief Executive Officer , Danon Disease , Operational Updates , Adhesion Deficiency I , American Society , Hematology Annual Meeting , Kinase Deficiency , Good Manufacturing Practice ,